Share this article
Share this article
With this approval, HUMIRA, an anti-TNF monoclonal antibody, offers pediatric patients from five years of age with moderately to severely active ulcerative colitis (UC) the first subcutaneous anti-TNF treatment option
1
Approval based on results from the pivotal Phase 3 ENVISION I study, the largest clinical trial in pediatric ulcerative colitis to date, showing HUMIRA provided significant rates of response and remission both at week 8 and 52
1,2
MONTREAL, April 22, 2021 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA
® (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids and/or azathioprine or 6-mercaptopurine or who are intolerant to such therapies.
With this approval, HUMIRA, an anti-TNF monoclonal antibody, offers pediatric patients from five years of age with moderately to severely active ulcerative colitis the first subcutaneous anti-TNF treatment option 1 Approval based on results from the pivotal Phase 3 ENVISION I study, the largest clinical trial in pediatric ulcerative colitis to date, showing HUMIRA provided significant rates of response and remission … With this approval, HUMIRA, an anti-TNF monoclonal antibody, offers pediatric patients from five years of age with moderately to severely active ulcerative colitis (UC) the first subcutaneous anti-TNF treatment option 1 Approval based on results from the pivotal Phase 3 ENVISION I study, the largest clinical trial in pediatric ulcerative colitis to date, showing HUMIRA provided significant rates of response and remission both at week 8 and 52
In Support of SB 111 and 112-Expanded access to expungement rstreet.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rstreet.org Daily Mail and Mail on Sunday newspapers.
by Clark Merrefield, The Journalist s Resource
April 13, 2021 h1 The multibillion-dollar costs of firearm injuries: Research and resources to consider /h1 p class byline by Clark Merrefield, The Journalist s Resource br April 13, 2021 /p p Mass shootings in the U.S. often attract national media coverage. They’re horrific, they upend the lives of numerous victims and families, and they’ve become increasingly common over the past two decades. /p p Less covered nationally, but deserving of more media attention, is the everyday toll of gun violence particularly injuries, which incur tens of billions of dollars in hospital costs and lost work time every year. /p
Apr 6, 2021
Testimony in support of HB 2684, relating to the expunction of arrest records and files and the issuance of orders of nondisclosure of criminal history record information for certain persons.
Chair Collier and members of the committee,
My name is Josiah Neeley. I am the Texas director of the R Street Institute, a center-right, free market think tank that supports limited effective government in many areas, including criminal justice reform. We support HB 2684.
This is a straightforward piece of legislation that fixes a hole left in current law regarding expungement or non-disclosure of prior criminal history. Texas allows an individual who has their conviction for a certain offense set aside after completing a period of community supervision to petition to have the court make their criminal record regarding that conviction non-disclosable. While still available to law enforcement, healthcare institutions and other selected entities, the order of non-disclosure makes t